1189-37-3
1189-37-3
Chemical Structure
Pristanic acid
- CAS No.: 1189-37-3
- Formula:C19H38O2
- Molecular Weight:298.50
IUPAC Name: 2,6,10,14-tetramethylpentadecanoic acid
InChIKey: PAHGJZDQXIOYTH-UHFFFAOYSA-N
SMILES: CC(C)CCCC(C)CCCC(C)CCCC(C)C(O)=O
Biological Activity: Pristanic acid is an endogenous metabolite present in Blood that can be used for the research of Alpha Methylacyl CoA Racemase Deficiency and Zellweger Syndrome[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Pristanic acid | 99.94% | Pristanic acid is an endogenous metabolite present in Blood that can be used for the research of Alpha Methylacyl CoA Racemase Deficiency and Zellweger Syndrome. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pristanic acid (Standard) | ≥98% | Pristanic acid (Standard) is the analytical standard of Pristanic acid (HY-113024). This product is intended for research and analytical applications. Pristanic acid is an endogenous metabolite present in Blood that can be used for the research of Alpha Methylacyl CoA Racemase Deficiency and Zellweger Syndrome. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pristanic acid-d6 (>90%) | Pristanic acid-d6 (>90%) is the deuterium labeled Pristanic acid (HY-113024). Pristanic acid is an endogenous metabolite present in Blood that can be used for the research of Alpha Methylacyl CoA Racemase Deficiency and Zellweger Syndrome. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pristanic acid-d3 | Pristanic acid-d3 is deuterium labeled Pristanic acid. Pristanic acid is an endogenous metabolite present in Blood that can be used for the research of Alpha Methylacyl CoA Racemase Deficiency and Zellweger Syndrome. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Lee N, et al. Endogenous toxic metabolites and implications in cancer therapy. Oncogene. 2020 Aug;39(35):5709-5720. [Content Brief]
- [2]. McLean BN, et al. A new defect of peroxisomal function involving pristanic acid: a case report. J Neurol Neurosurg Psychiatry. 2002 Mar;72(3):396-9. [Content Brief]
- [3]. Baumgartner MR, et al. Clinical approach to inherited peroxisomal disorders: a series of 27 patients. Ann Neurol. 1998 Nov;44(5):720-30. [Content Brief]
